Contents
Academy · Research Data, Analytics & AI · Readjusting Clinical trials in COVID 19 Era
Readjusting Clinical Trials in the COVID-19 Era: FDA Guidance and the Documentation of Protocol Deviations
The pandemic did not pause ongoing trials. It forced sponsors to decide, mid-trial, which protocol deviations preserved scientific validity and which ones would have to be disclosed as a limitation -- in writing, in real time.
Readjusting clinical trials during the COVID-19 pandemic refers to the protocol modifications -- remote visits, alternative drug delivery, altered monitoring, missed assessments -- that regulators explicitly anticipated and addressed through emergency guidance, rather than leaving sponsors to interrupt trials altogether or to make undocumented ad hoc changes.
Learning objectives
- The specific scope of the US Food and Drug Administration (FDA) guidance on clinical trial conduct during COVID-19.
- Why documentation of protocol deviations became a central requirement, not an afterthought.
- The difference between a planned protocol amendment and an emergency deviation, and why each required different handling.
- The implications of this guidance for the interpretation of a trial’s pandemic-era data.
Common misconceptions
- “Any pandemic-related change to how a trial was run should just be noted informally.” FDA guidance on clinical trial conduct during COVID-19 specifically required that protocol deviations arising from the pandemic be documented, including their reason and anticipated impact on safety and the statistical analysis plan, not simply noted informally in a trial master file.
- “A trial disrupted by the pandemic should be treated as equivalent to one run as originally planned.” Guidance from this period explicitly expected sponsors to assess and disclose how pandemic-related disruptions -- missed visits, alternative assessment methods, site closures -- could affect the interpretation of safety and efficacy data, rather than treating the disrupted and undisrupted portions of a trial as interchangeable.
Scope of the US Food and Drug Administration guidance
The FDA's guidance on the conduct of clinical trials of medical products during the COVID-19 public health emergency, issued and subsequently updated from March 2020, addressed specific, concrete disruptions sponsors were facing: participants unable to attend site visits, site closures or staff reassignment, interruptions to the supply chain for the investigational product, and the need for alternative methods of safety monitoring, such as remote or local assessments in place of visits to the investigational site. The guidance's approach was to anticipate these specific situations and provide a framework for handling each, rather than leaving sponsors to decide unilaterally and inconsistently.
Documentation of protocol deviations
A central theme of the guidance was explicit documentation: sponsors were expected to describe, for each affected trial, the contingency measures implemented, the rationale, and an assessment of how those measures might affect the safety and efficacy data being collected, with these changes integrated into the statistical analysis plan where protocol modifications were made in response to the pandemic. This requirement treated documentation not as a bureaucratic afterthought but as the mechanism that let the eventual trial report distinguish pandemic-related protocol deviations from genuine treatment or safety signals.
Implications for the interpretation of pandemic-era trial data
Because the guidance expected sponsors to assess and disclose the impact of pandemic-related disruptions on interpretation, a trial report covering this period should explicitly separate what was observed under the original protocol from what was observed under contingency measures, and discuss whether and how that separation affects confidence in the overall result. Treating pandemic-era and non-pandemic-era data as simply pooled and equivalent, without this disclosure, understates a limitation the guidance specifically anticipated sponsors would need to address.
Key points
Key points
Readjusting trials during COVID-19 meant following emergency regulatory guidance that anticipated specific disruptions -- missed visits, site closures, alternative monitoring -- and required sponsors to document the resulting protocol deviations and assess their impact on safety and efficacy interpretation, rather than treating disrupted and undisrupted trial periods as equivalent without disclosure.
Practical application
Practical application
- Each pandemic-related deviation should be documented with its rationale and an impact assessment. The record should state the contingency measure used, the reason for its use and an explicit assessment of its likely effect on the specific safety or efficacy data affected.
- Documented deviations should be integrated into the statistical analysis plan. The analysis plan should be updated to specify how pandemic-related protocol modifications will be handled in the final analysis, rather than this being addressed only after data lock.
- The distinction between disrupted and undisrupted data should be disclosed in reporting. The trial report should state explicitly which portions of the data were collected under contingency measures and discuss the implications for interpretation.
Frequently asked questions
No; it was written to address ongoing trials disrupted mid-course as well as new trials initiated during the public health emergency.
Not automatically; the guidance's framework was about documentation and impact assessment, which could support continued use of the data with appropriate caveats, rather than mandating exclusion by default.
The specific emergency guidance was tied to the COVID-19 public health emergency period; its underlying principle -- documenting and assessing the impact of unplanned protocol deviations -- remains broadly applicable good practice for any trial disruption.
References
- U.S. Food and Drug Administration. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency. 2020 (updated). read 10 October 2026. View FDA guidance
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). Readjusting Clinical Trials in the COVID-19 Era: FDA Guidance and the Documentation of Protocol Deviations. Pubrica. https://pubrica.com/academy/concepts-definitions/readjusting-clinical-trials-in-covid-19-era/
Pubrica Academy. “Readjusting Clinical Trials in the COVID-19 Era: FDA Guidance and the Documentation of Protocol Deviations.” Pubrica, 10 Oct. 2026, pubrica.com/academy/concepts-definitions/readjusting-clinical-trials-in-covid-19-era/.
Pubrica Academy (2026) Readjusting Clinical Trials in the COVID-19 Era: FDA Guidance and the Documentation of Protocol Deviations. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/readjusting-clinical-trials-in-covid-19-era/ (Accessed: 15 October 2026).
Pubrica Academy. “Readjusting Clinical Trials in the COVID-19 Era: FDA Guidance and the Documentation of Protocol Deviations.” Pubrica. October 10, 2026. https://pubrica.com/academy/concepts-definitions/readjusting-clinical-trials-in-covid-19-era/
Pubrica Academy, ‘Readjusting Clinical Trials in the COVID-19 Era: FDA Guidance and the Documentation of Protocol Deviations’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/concepts-definitions/readjusting-clinical-trials-in-covid-19-era/> accessed 15 October 2026.
Pubrica Academy. Readjusting Clinical Trials in the COVID-19 Era: FDA Guidance and the Documentation of Protocol Deviations. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/readjusting-clinical-trials-in-covid-19-era/
Pubrica Academy, “Readjusting Clinical Trials in the COVID-19 Era: FDA Guidance and the Documentation of Protocol Deviations,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/readjusting-clinical-trials-in-covid-19-era/
@misc{readjusting_clinical_trials_covid_era_2026,
author = {{Pubrica Academy}},
title = {Readjusting Clinical Trials in the COVID-19 Era: FDA Guidance and the Documentation of Protocol Deviations},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/readjusting-clinical-trials-in-covid-19-era/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Pandemic-era protocol deviation log stub
Use to document trial disruptions during a declared public health emergency.
Deviation description: ____ Affected participants/sites: ____ Contingency measure used: ____ Rationale: ____ Assessed impact on safety data: ____ Assessed impact on efficacy/statistical analysis: ____ Updated in statistical analysis plan? Y/N
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s clinical-trials and regulatory-writing teams document pandemic- or emergency-related protocol deviations to the standard expected under FDA guidance, and prepare the resulting trial report so that disrupted and undisrupted data are clearly distinguished.